SC 13G 1 alexion.txt ALEXION PHARMACEUTICALS INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Alexion Pharmaceuticals, Inc ------------------------- (Name of Issuer) COMMON STOCK -------------------------------- (Title of Class of Securities) 015351109 ---------------- (CUSIP Number) August 5th, 2003 --------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |X| Rule 13d-1(c) |_| Rule 13d-1(d) The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). - ------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON PICTET FUNDS - BIOTECH - ------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |X| - ------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg - ------------------------------------------------------------------------- 5 SOLE VOTING POWER 990'028 --------------------------------------------------------- NUMBER OF 6 SHARED VOTING POWER SHARES BENEFICIALLY OWNED BY --------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON WITH --------------------------------------------------------- 8 SHARED DISPOSITIVE POWER - ------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 990'028 - ------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |_| - ------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.44% - ------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* INVESTMENT FUND - ------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT Item 1. (a) Name of Issuer: Alexion Pharmaceuuticals, Inc (b) Address of Issuer's Principal Executive Offices: 352 Knotter Drive Cheshire, Connecticut 06410 United States Item 2. (a) Name of Person Filing: PICTET FUNDS - BIOTECH (b) Address of Principal Business Office or, if none, Residence: Luxembourg (c) Citizenship: Luxembourg (d) Title of Class Securities: Common Stock (e) CUSIP Number: 015351109 Item 3. Not applicable. Item 4. Ownership (a) Amount Beneficially Owned: 990'028 (b) Percent of Class: 5.44%. (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: (ii) shared power to vote or to direct the vote: (iii) sole power to dispose or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of the Group Not applicable. Item 10. Certification By signing below I certify that, to the best if my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquire and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: August 5th, 2003 Patrick SCHOTT Tom OLINGER -------------- -------------- -------------- -------------